Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

DRAK2 anticorps (C-Term)

STK17B Reactivité: Humain WB, IF, EIA Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN499770
  • Antigène Voir toutes DRAK2 (STK17B) Anticorps
    DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
    Épitope
    • 10
    • 7
    • 6
    • 6
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term
    Reactivité
    • 41
    • 16
    • 8
    • 1
    • 1
    • 1
    Humain
    Hôte
    • 38
    • 2
    • 1
    Lapin
    Clonalité
    • 40
    • 1
    Polyclonal
    Conjugué
    • 20
    • 4
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp DRAK2 est non-conjugé
    Application
    • 29
    • 25
    • 8
    • 3
    • 3
    • 3
    • 1
    Western Blotting (WB), Immunofluorescence (IF), Enzyme Immunoassay (EIA)
    Specificité
    DRAK2 antibody was raised against a peptide corresponding to amino acids 351 to 365 of human DRAK2. It has no cross responses to DAP or ZIP kinases.
    Purification
    Ion exchange chromatography
    Immunogène
    Human DRAK2 (C-Terminus) Peptide
    Isotype
    IgG
    Top Product
    Discover our top product STK17B Anticorps primaire
  • Indications d'application
    ELISA. Western Blot: 1/500 to 1/1000. An approximately 45 kDa band can be detected. Theapproximately 70 kDa band is probably non-related to DRAK2 although it is peptideblockable. Immunocytochemistry.
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.
    Restrictions
    For Research Use only
  • Buffer
    PBS containing 0.02 % sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C
    Stockage commentaire
    Store the antibody undiluted at 2-8 °C.
  • Antigène
    DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
    Autre désignation
    STK17B / DRAK2 (STK17B Produits)
    Synonymes
    anticorps zgc:65989, anticorps STK17B, anticorps DRAK2, anticorps Drak2, anticorps 3110009A03Rik, anticorps AI120141, anticorps serine/threonine kinase 17b (apoptosis-inducing), anticorps serine/threonine kinase 17b, anticorps stk17b, anticorps STK17B, anticorps Stk17b
    Sujet
    Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues (1).Synonyms: DAP kinase-related apoptosis-inducing protein kinase 2, Serine/threonine-protein kinase 17B
    ID gène
    9262
    UniProt
    O94768
Vous êtes ici:
Support technique